Plain-English translation of NCT06263387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is collecting information about how a combination of two medications called Venetoclax and Azacitidine works in everyday clinical practice for adults newly diagnosed with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. The researchers want to understand how well this treatment combination helps patients and what side effects occur in real-world settings, not just in controlled research environments. This information will help doctors and healthcare decision-makers better understand whether this medication is right for patients like you.
When this medication was first approved, it showed promise in clinical trials for patients with AML who couldn't receive aggressive chemotherapy. However, researchers need to understand how the treatment works in everyday practice—with diverse patient populations and real-world conditions—to make sure it's truly helpful and safe for the people who need it most.
If you qualify, you would already be taking the medication combination as part of France's early access program or continuing it after the program ended. This study involves sharing your medical records and treatment information with researchers so they can track how well the medication works for you over time. You would not need to do anything extra—the study is documenting your care as it happens in your regular doctor's visits.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France